罗洁 刘莉莉 周亮

摘 要 目的：分析康柏西普联合玻璃体切除术治疗进展型增殖期糖尿病视网膜病变（DR）的疗效。方法：选取进展型增殖期DR患者84例，随机分为对照组和研究组各42例。对照组行传统玻璃体切除术，研究组行康柏西普联合玻璃体切除术。比较两组手术效果及预后。结果：术前视力、黄斑厚度两组比较差异无统计学意义（P>0.05）。手术后，研究组视力、黄斑厚度改善幅度大于对照组；且研究组手术时间，术中出血、电凝、硅油及医源性裂孔发生率均低于对照组；研究组术后前房积血、玻璃体腔再出血发生率低于对照组（P<0.05）。结论：康柏西普联合玻璃体切除术治疗进展型增殖期DR，可降低术中医源性损伤风险，手术预后效果较好。

关键词 康柏西普 玻璃体切除术 糖尿病性视网膜病变

中图分类号：R988.1； R587.2 文献标志码：B 文章编号：1006-1533（2021）07-0035-02

The effect of conbercept combined with vitrectomy in the treatment of progressive proliferative diabetic retinopathy

LUO Jie， LIU Lili， ZHOU Liang

（Department of Fundus Disease， Eye Hospital affiliated to Nanchang University， Nanchang 330001， China）

ABSTRACT Objective： To analyze the efficacy of conbercept combined with vitrectomy in the treatment of progressive proliferative diabetic retinopathy. Methods： A total of 84 patients with progressive proliferative diabetic retinopathy were selected and randomly divided into a control group and a study group with 42 cases each. The control group underwent traditional vitrectomy while the study group underwent conbercept combined with vitrectomy. The surgical effect and prognosis were compared between the two groups. Results： There were no statistically significant differences in preoperative visual acuity and macular thickness between the two groups before treatment （P>0.05）. The improvement in the visual acuity and macular thickness was significant better and the operation time， intraoperative bleeding， electrocoagulation， silicone oil and iatrogenic holes were significantly lower in the study group than the control group after the operation （P<0.05）. The incidence of postoperative anterior chamber hemorrhage and vitreous cavity rebleeding was significantly decreased in the study group. Conclusion： Conbercept combined with vitrectomy for the treatment of patients with progressive proliferative diabetic retinopathy can reduce the risk of iatrogenic injury during the operation with good prognosis.

KEy WORDS conbercept； vitrectomy； diabetic retinopathy

進展型增殖期糖尿病视网膜病变（diabetic retinopathy，DR）是临床高发的糖尿病眼部并发症，也是此类患者致盲的主要原因，受高血糖水平影响的视网膜血管组织可出现增生，刺激视网膜纤维化进展从而致盲[1]。玻璃体切除术作为此类疾病的主要治疗措施，具有较好的治疗效果，但术中存在的医源性损伤，易对手术预后造成不良影响，故应针对此类医源性损伤予以相应的辅助改善措施，改善手术的安全及效果[2]。

1 资料与方法

1.1 一般资料

选取2018年1月—2019年6月南昌大学附属眼科医院收治的进展型增殖期DR患者共84例，将其随机分为对照组和研究组各42例。其中对照组男22例，女20例，共42眼；年龄52～73岁，平均年龄（62.54±3.68）岁；糖尿病病程3～7年，平均病程（5.02±1.48）年；增殖性视网膜病变（proliferative diabetic retinopathy，PDR）病程6～11个月，平均病程（8.52±2.04）个月。研究……